Although truncated mutations account for only a small proportion of clinical tumor samples, the relatively higher frequency of HTATSF1 deletion mutations (15%) or copy number loss of CSNK2A1 and TOPBP1 (5–25%) may further expand its application as a potential therapeutic strategy for breast and lung tumors. This evidence concerns the gene HTATSF1 and neoplasm.